Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Trial
Phase 4
Completed
Dec. 12, 2022
Use of BART Coupled With EEG in the Early Diagnosis of Behavioral Disorders in Parkinson's Disease
Trial
N/A
Unknown
Dec. 11, 2022
Exergames in In-patient Rehabilitation
Trial
N/A
Completed
Dec. 8, 2022
The Effects of Telerehabilitation-based Exercise Trainings on Gait and Balance in Parkinson's Patients
Trial
N/A
Completed
Dec. 8, 2022
Effects of Home Rehabilitation of Balance Based on Functional Exercises in People With Parkinson's Disease
Trial
N/A
Unknown
Dec. 7, 2022
The Effect of Multi-target Magnetic Stimulation on Freezing Gait in PD
Trial
N/A
Unknown
Dec. 5, 2022
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
Trial
Phase 3
Completed
Dec. 1, 2022
Neuromelanin MRI: A Progression Marker in Early PD
Trial
N/A
Unknown
Nov. 29, 2022
Benefits of Different Exercise Types to Enhance Walking for PD
Trial
N/A
Unknown
Nov. 29, 2022
Opicapone Treatment Initiation Open-Label Study
Trial
N/A
Completed
Nov. 27, 2022
Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis
Trial
N/A
Completed
Nov. 27, 2022
Telerehabilitation Based Exercise Training in Parkinson's Patients
Trial
N/A
Unknown
Nov. 17, 2022
Effects of Whole Body Vibration in Parkinson's Disease Symptoms
Trial
N/A
Unknown
Nov. 16, 2022
A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia
Trial
N/A
Withdrawn
Nov. 16, 2022
Idiopathic Parkinson's Progression and Dopamine Transporter SPECT
Trial
N/A
Completed
Nov. 16, 2022
Taxonomy of Neurorehabilitation Treatments and Outcome Measures: a Multicentre Italian Study
Trial
N/A
Completed
Nov. 14, 2022
Auditory Slow Wave Enhancement in Parkinson Disease and Mild Cognitive Impairment
Trial
N/A
Unknown
Nov. 14, 2022
Treatment Burden in Parkinson's
Trial
N/A
Completed
Nov. 13, 2022
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
Trial
Phase 2
Completed
Nov. 9, 2022